drugset / Trial / NCT04814368

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368

Phase 2 Terminated 23 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).

Timeline

Start
2021-08-27
Primary completion
2024-06-24
Completion
2024-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 600 mg Other
Subject LNA043 Unknown 40 mg Other

Indications